Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > ONCY accumulated deficit (Tax losses applied to a buyout)
View:
Post by Noteable on Jan 01, 2024 3:55pm

ONCY accumulated deficit (Tax losses applied to a buyout)

ONCY's accumulated deficit a/o September 30, 2023 was approximately $442 million.

ONCY's estimated accumulated deficit a/o December 31, 2023 is approximately $450 Million. 

Consequently any buyout offer for ONCY would take into account the accumulated deficit of  approximately $0.5 Billion in the price for the company such that a US$ 7.5 Billion offer for ONCY would effectively be approximately US$7 Billion.when taking into account the acquired benefit of the accumulated taxes loss that would come with the acquisition of ONCY.
Comment by Noteable on Jan 10, 2024 12:44pm
ONCY's estimated accumulated deficit a/o December 31, 2023 is approximately $450 Million
Comment by Noteable on Jan 25, 2024 11:13am
In comparison to CG Oncology's $380 million raise in their IPO announced on January 25, 2024, ONCY's estimated accumulated deficit a/o December 31, 2023 is approximately $450 Million
Comment by Noteable on Feb 25, 2024 11:23am
ONCY's estimated accumulated deficit a/o December 31, 2023 is approximately $450 Million, ONCY's accumulated deficit correlates to research and development expenses are eligible for the Orphan Drug Tax Credit which provides t he sponsor company a 25% tax credit to offset research and development costs (qualified clinical testing). It is intended to incentivize biotechnology ...more  
Comment by Noteable on Feb 25, 2024 11:46am
This value of approximately US$ 6.25+ per share a/o December 2023 is a valuation point that will be factored into the calculation of ONCY's comprehensive purchase enterprise value in arriving at the company's starting acquisition price target.
Comment by Noteable on Mar 09, 2024 1:26pm
https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-ord-shs?postid=35924492 https://stockhouse.com/news/press-releases/2024/03/07/oncolytics-biotech-xae-reports-fourth-quarter-and-full-year-2023-financial
Comment by Noteable on Feb 16, 2024 1:45pm
ONCY's estimated accumulated deficit a/o December 31, 2023 is approximately $450 Million making this dollar amount of some consequence in any buyout offer for ONCY. The accumulated deficit of approximately $0.5 Billion in a US$ 7.5 Billion offer for ONCY would effectively be approximately US$7 Billion in cost to the acquiring company, since the accumulated deficit could be used to off-set any ...more  
Comment by Noteable on Feb 16, 2024 2:20pm
The accumulated deficit is worth a minimum of US$ 4.25 per share which clearly demonstrates that ONCY's present share price is being significantly held down, as I have pointed out in previous posts.
Comment by Noteable on Feb 16, 2024 2:28pm
This accumulated deficit is one of the reasons why analysts covering ONCY have a near term price target of $5+ per share.
Comment by Noteable on Feb 16, 2024 2:44pm
Should read: "The accumulated deficit represents an underlying value of at least US$ 4.25 per share " ..... which is one of the reasons why analysts covering ONCY have a near term target value of at least $5+ per share.
Comment by Noteable on Feb 19, 2024 12:33pm
The basic underlying value of ONCY based simply on the company's accumulated deficit, and nothing more, is approximately US $5 per share, which indicates why analysts have a near term target of US$5 per share price, and further indicates that the stock price of ONCY is being significantly throttled by some particular player/s, such as Quentin30 and the team of operatives he identifies with
Comment by Noteable on Feb 20, 2024 12:25pm
For comparision IOVA has an accumulated deficit of US$1.463 Bln that translated to an underlying tax off-set of US$5.95 per share. Through 2023 the trading range for IOVA stock in 2023 was between US$5.71 and US$7.98 per share, which reflected the underlying accumulated deficit off-set of US$5.95 per share. Such evidence confirms that ONCY's share price has been intentionally held down by ...more  
Comment by 13X2413 on Feb 20, 2024 12:32pm
If 3 or 4 people can affect the price of this stock,  this company is in trouble. Stop with the manipulation conspiracy theories. Start living in reality, this stock needs a big kick in the pants. The sooner the better. 
Comment by Noteable on Feb 20, 2024 1:13pm
Wolves in sheeps' clothing come with different messages, but each seek counter the fair value of the company and the share price. Right Canadafan?.
Comment by Noteable on Feb 20, 2024 6:46pm
Wolves in sheep's clothing come with different messages, but each seeking to counter the fair value of the company and the share price. Right Canadafan? And the other operatives who have recently said that they don't read the stockhouse message board.
Comment by 13X2413 on Feb 20, 2024 7:31pm
Since I'm not a James Bond operative, I'm dying to know what your message is. What makes your operative like opinion worthy of any more belief than other opinions? In my eyes, the others carry more weight as a result of what the ACTUAL value of the stock has done over the past few months.  I can't take your FAIR value to the bank. 
Comment by Buckhenry on Feb 20, 2024 9:55pm
Unnoteable needs to put more cologne on his sh!t. He thinks his dung does not stink. 
Comment by armedescapade on Feb 20, 2024 8:30pm
This post has been removed in accordance with Community Policy
Comment by Noteable on Feb 20, 2024 9:00pm
Only someone like you would seem to know what greedy eyes and little brain means. Perhaps you should switch from eating too many French fries with your greedy little brain like-minded "operatives"
Comment by armedescapade on Feb 21, 2024 12:42pm
This post has been removed in accordance with Community Policy
Comment by Buckhenry on Feb 20, 2024 3:18pm
This site is no different than the other stocks I watch. There is an unnoteable for every stock saying that those who don't adhere to his narrative are manipulators. They have to pass the blame to someone else. You can't handle reality. 
Comment by Buckhenry on Feb 20, 2024 4:08pm
Some people need to be right always. They cannot stand to lose an argument. They won’t admit defeat in the face of compelling evidence against their position. Even having the last word may not be enough for them if they believe the other side has gotten tired of the discussion and stopped arguing without conceding their point. In that case, they may insist on taking up the issue again later.  ...more  
Comment by Noteable on Feb 20, 2024 12:32pm
https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor
Comment by Noteable on Feb 20, 2024 1:19pm
And for comparision IOVA has an accumulated deficit of US$1.463 Bln that translated to an underlying tax off-set of US$5.95 per share. Through 2023 the trading range for IOVA stock in 2023 was between US$5.71 and US$7.98 per share, which reflected the underlying accumulated deficit off-set of US$5.95 per share.  In 2022 IOVA traded between US19.09 and US$6.18. And in 2021 IOVA traded at a ...more  
Comment by Noteable on Feb 20, 2024 8:07pm
In response and as posted beforehand for further comparision,  IOVA has an accumulated deficit of US$1.463 Bln that translated to an underlying tax off-set of US$5.95 per share. Through 2023 the trading range for IOVA stock in 2023 was between US$5.71 and US$7.98 per share, which reflected the underlying accumulated deficit off-set of US$5.95 per share.    In 2022 IOVA traded ...more  
Comment by Noteable on Feb 21, 2024 6:33pm
ONCY raised approximately $450 million over its lifetime and not $3/4 Billion as one has tried to pass-off. This $450 million is reported in ONCY's financial statements as the "accumulated deficit".  The accumulated deficit represents a basic underlying value of at least US$ 4.25 per share  ..... which is one of the reasons why analysts covering ONCY have a near term ...more  
Comment by armedescapade on Feb 21, 2024 11:30pm
This post has been removed in accordance with Community Policy
Comment by armedescapade on Feb 22, 2024 12:57pm
This post has been removed in accordance with Community Policy
Comment by Azzak34 on Feb 22, 2024 1:12pm
Eeugghh, what a slimy post. Yikes, how many institutional investors do we have? Yikes, what's in our pipeline? Yikes, who says Yikes anymore? 
Comment by armedescapade on Feb 22, 2024 2:52pm
This post has been removed in accordance with Community Policy
Comment by Azzak34 on Feb 22, 2024 3:01pm
Haha here's my main issue with you folks. Most of your posts read like clues in a cryptic crossword. It's total garbage. It doesn't come off smart, stop trying so hard babe, it's not working.  Armedescapade, now what is the meaning behind that moniker you've given yourself. Are you another of the orange man right wing nuts that frequent Stocktwits? 
Comment by inthno on Feb 22, 2024 1:15pm
For accounting purposes the value of the accumulated deficit is really only worth what the acquiring companies tax rate is at which even if at 50% is only then about 250 million and not the total deficit of 450 million as the 250 million would be the realized value in any negotiation. BTW I am expecting a pr either tomorrow or next week announcing the q4 and year end 2023 as these dates would be ...more  
Comment by Noteable on Feb 22, 2024 7:14pm
During a merger-acquisition transaction, the acquired company frequently accumulated tax losses (accumulated deficit) representing potential tax savings that the acquiring company could use if it obtained the transfer thereof.  https://us.sagepub.com/sites/default/files/upm-assets/5004_book_item_5004.pdf On a liquidation of an acquired company or the amalgamation of the acquired ...more  
Comment by inthno on Feb 22, 2024 8:36pm
Remember that it states in the article that you posted is that it reduces the taxable income by the amount accordingly so the company then saves whatever the amount their tax bracket is and that is the amount that the accumulated loss is. Simple accounting and that is how it is applied in business or at least that is how my accountant does it. Also remember that the accumulated deficit is 450 ...more  
Comment by Noteable on Feb 22, 2024 8:44pm
It has nothing to do with any tax bracket, as you keep wrongly stating. Read the KPMG opinion. 
Comment by inthno on Feb 22, 2024 9:16pm
No problem and you can read it how you want but from the last line of the article you posted. The benefit is that it lowers the taxable income in the second year to $2.4 million. Quite simply stating that it lowers the taxable income and you pay tax on the bracket that applies to you or your company. Bottom line is that there is value to the accumulated amazingly large deficit but it is in ...more  
Comment by Noteable on Feb 22, 2024 9:46pm
You obviously didn't understand what was said when I wrote the below commentary that the Carryforward Losses do not appky, in diametrically opposed contrast to what you tried to imply. And since a Big Pharma company has profits far in excess of ONCY's accumulated deficit, the following (below referenced) Loss Carryforward provisions do not apply.
Comment by Noteable on Feb 22, 2024 9:54pm
Furthermore I cited the accounting firm KPMG's opinion on the matter surrounding a corporate acquisition, while you tried to pass off your bewildered understanding of how your accountant handled your personal matter.
Comment by Noteable on Feb 22, 2024 10:03pm
And US$2.81 per share is what ONCY can raise at its discretion and at anytime by calling its option on the warrants that were tied to the US $15 million deal, thus giving ONCY access to a further US$21 million, whenever ONCY or ONCY's acquirer chooses.
Comment by Noteable on Feb 22, 2024 10:05pm
Should read "... that were tied to the US $15 million deal Anson Funds Management deal ..."
Comment by inthno on Feb 22, 2024 10:28pm
I.do not understand why u get so confrontational as I was trying to say is what it is and worth something in a buyout. U have your thoughts and I have mine but no matter how u look at it what you can wrote off against gains and what u save on taxes as a result are 2 different figures.  So when a company writes off 450 million dollars you are saying that they save 450 million dollars in taxes. ...more  
Comment by Noteable on Feb 23, 2024 10:53am
inthno .. No I am not saying what you are stating. And no I was not talking about the treatment of capital gains/losses as you would in your personal account. You don't seem to understand the principles of corporate tax transfers associated with corporate mergers and acquisitions. What I am talking about is the transfer of an acquired company's  accumulated deficit off of their ...more  
Comment by Noteable on Feb 23, 2024 11:03am
The net benefits of an acquired company's accumulated deficit transfer to an acquiring company's balance sheet is that the acquiring company can use this transaction to offset present/future net profits AND the value of this accumulated deficit is factored into the price paid for the acquired company by raising the final offer. And in raising the final offer price, shareholders benefit ...more  
Comment by 13X2413 on Feb 23, 2024 11:47am
Buyers, where are you???? Doesn't anyone realize that Noteable says the intrinsic value is $5US. Getting close to $1 CDN. now. How can you pass on a deal like this. 
Comment by Quentin30 on Feb 23, 2024 1:13pm
ah I gor it now, thanks Notable... So because ONCY has had 25 years of losses, it's valuable to a company that makes profit... hmmm, And yet still no-one want to buy us...!!
Comment by Azzak34 on Feb 23, 2024 1:19pm
Haha what a silly Billy you are Quentypoo.  Have you ever answered why you keep any shares at all? 
Comment by 13X2413 on Feb 22, 2024 8:59pm
$2.81 would be like a lottery win at this point. I'll take it! 
Comment by armedescapade on Feb 22, 2024 10:28pm
This post has been removed in accordance with Community Policy
Comment by Azzak34 on Feb 23, 2024 3:19am
You know who also talks in these incoherent rambles? Our old friend Stocks4thoughts.  Stocks can you produce a codex for the tripe you post please? 
Comment by Lesalpes29 on Feb 23, 2024 7:28am
Until a substantial NR all the talks around a multi billions buyout is futil. It's why I have unstable on ignore... is shooting the same posts weeks after weeks and nothing is moving. This clown is blasting almost everybody even Canadafan... GLTAL 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities